TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide
New messaging reflects TFS's commitment to patient-centered clinical research and global partnerships
The refreshed mission—to empower partners to advance treatments that promote global health and well-being—marks a deepened focus on transforming patient care through innovative drug development. With patient-centered care at its core, TFS reinforces its role as a CRO that not only supports the pharmaceutical industry but drives meaningful impact on global health.
TFS specializes in key therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology, making it a standout partner among global mid-sized CROs. These focus areas enable TFS to address some of the most pressing health challenges while delivering tailored clinical research solutions for its partners.
TFS's new mission was shaped by a diverse focus group, who helped redefine the company's identity, emphasizing sustainability, diversity, and the global impact of clinical trials. This inclusive approach ensures that TFS is aligned with the evolving needs of its partners while maintaining a patient-centered and people-first philosophy.
"Our new mission and tagline are more than a rebranding exercise; they define our purpose," said Patrik Darsund,
For over two decades, TFS has built a reputation for delivering clinical research excellence, and this new mission reinforces its ongoing evolution. By combining the global reach of a large CRO with the flexibility and responsiveness of a mid-sized organization, TFS continues to support its clients and partners in navigating the complexities of the healthcare landscape.
"TFS is at a pivotal moment in its evolution," said Dr.
CONTACT:
Executive Director, Marketing & Communications
[email protected]
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.com/news-releases/tfs-healthscience-unveils-mission-to-empower-partners-and-enrich-lives-worldwide-302252995.html
SOURCE TFS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility
- FingerMotion Announces Non-Binding Three-Party MOU with Lyken.AI and BlueFlare and Provides Update on Alberta Corridor Gas-Supply Discussions
- OPTICAL CABLE CORPORATION SCHEDULES CONFERENCE CALL TO DISCUSS THIRD QUARTER OF FISCAL YEAR 2026 RESULTS
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share